Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 in metastatic NSCLC with activated PI3K pathway
NCT01297491Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2011
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 2 trial of buparlisib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started May 2011; status: completed.
02
Drugs
buparlisib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01297491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01297491.